-
公开(公告)号：US20220380451A1
公开(公告)日：2022-12-01
申请号：US17835321
申请日：2022-06-08
Applicant: GLAXOSMITHKLINE LLC
Inventor： Jahanara AZMI , Jonathan STEINFELD
Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases in pediatric subjects, and related methods.
-
公开(公告)号：US20200157055A1
公开(公告)日：2020-05-21
申请号：US16455106
申请日：2019-06-27
Applicant: GlaxoSmithKline, LLC
Inventor： Kevin J. DUFFY , Duke M. FITCH , Jian JIN , Ronggang LIU , Antony N. SHAW , Kenneth WIGGALL
IPC: C07D239/60 , A61K31/515 , C07D239/54 , C07D239/62 , C07D401/04 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D413/10 , C07D417/10 , C07D239/22
Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
-
公开(公告)号：US20190135829A1
公开(公告)日：2019-05-09
申请号：US16240659
申请日：2019-01-04
Applicant: GlaxoSmithKline LLC
Inventor： Mui Cheung , Raghuram Tangirala
IPC: C07D498/04 , C07D519/00
CPC classification number: C07D498/04 , C07D519/00
Abstract: This invention relates to methods for the preparation of a compound which is an inhibitor of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1).
-
公开(公告)号：US10238678B2
公开(公告)日：2019-03-26
申请号：US14803478
申请日：2015-07-20
Applicant: GlaxoSmithKline LLC
Inventor： Jill Walker , Christian Voitenleitner
IPC: A61K31/69 , A61K38/21 , A61K45/06 , A61K31/343 , A61K31/7056
Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
-
公开(公告)号：US20180289800A1
公开(公告)日：2018-10-11
申请号：US16008421
申请日：2018-06-14
Applicant: GLAXOSMITHKLINE LLC
Inventor： Diane Mary COE , Stephen Allan SMITH
IPC: A61K39/39 , C07D487/04 , A61K39/00 , A61K31/519 , A61K31/437 , A61K31/52
Abstract: Compounds of formula (I) and salts thereof: wherein R1 is n-C1-6alkyl or C1-2alkoxyC1-2alkyl-, R2 is halo, OH or C1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
-
Patent Agency Ranking
公开(公告)号：US09957271B2
公开(公告)日：2018-05-01
申请号：US14353096
申请日：2012-10-19
Applicant: GlaxoSmithKline, LLC
Inventor： Rebecca L. Casaubon , Radha Narayan , Christopher Oalmann , Chi B. Vu
IPC: C07D487/04 , A61K45/06 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/5377 , C07D491/107 , C07D495/10 , C07D519/00
CPC classification number: C07D487/04 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D491/107 , C07D495/10 , C07D519/00 , A61K2300/00 , A61K31/56
Abstract: Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
-
公开(公告)号：US20170367648A1
公开(公告)日：2017-12-28
申请号：US15645646
申请日：2017-07-10
Inventor： Marc K. HELLERSTEIN , William J. EVANS
CPC classification number: A61B5/4869 , A61B5/107 , A61B5/15 , A61B5/4519 , A61B10/007 , G01N30/7233 , G01N33/493 , G01N33/70 , H01J49/0036 , H01J49/004
Abstract: The present invention is based on the finding that enrichment of D3-creatinine in a urine sample following; oral administration of a single defined dose of D3-creatine can be used to calculate total-body creatine pool size and total body skeletal muscle mass in a subject. The invention further encompasses methods for detecting creatinine and D3-creatinine in a single sample. The methods of the invention find use, inter alia, in diagnosing disorders related to skeletal muscle mass, and in screening potential therapeutic agents to determine their effects on muscle mass.
-
公开(公告)号：US09738658B2
公开(公告)日：2017-08-22
申请号：US15370051
申请日：2016-12-06
Applicant: GlaxoSmithKline LLC
Inventor： Mui Cheung , Raghuram S. Tangirala
IPC: C07D498/04 , C07D519/00
CPC classification number: C07D498/04 , C07D519/00
Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.
-
公开(公告)号：US09737260B2
公开(公告)日：2017-08-22
申请号：US15098217
申请日：2016-04-13
Inventor： Marc K. Hellerstein , William Evans
IPC: G01N33/70 , G01N33/48 , A61B10/00 , A61B5/00 , H01J49/00 , A61B5/107 , G01N30/72 , A61B5/15 , G01N33/493
CPC classification number: A61B5/4869 , A61B5/107 , A61B5/15 , A61B5/4519 , A61B10/007 , G01N30/7233 , G01N33/493 , G01N33/70 , H01J49/0036 , H01J49/004
Abstract: The present invention is based on the finding that enrichment of D3-creatinine in a urine sample following oral administration of a single defined dose of D3-creatine can be used to calculate total-body creatine pool size and total body skeletal muscle mass in a subject. The invention further encompasses methods for detecting creatinine and D3-creatinine in a single sample. The methods of the invention find use, inter alia, in diagnosing disorders related to skeletal muscle mass, and in screening potential therapeutic agents to determine their effects on muscle mass.
-
公开(公告)号：US09649307B2
公开(公告)日：2017-05-16
申请号：US15186633
申请日：2016-06-20
Applicant: GlaxoSmithKline LLC
Inventor： William Henry Miller , Xinrong Tian , Sharad Kumar Verma
IPC: A61K31/496 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/501 , A61K31/5383 , A61K31/551 , A61K31/4545 , A61K31/541 , A61K31/405 , C07D401/12 , C07D401/14 , C07D405/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D498/04 , C07D409/14 , C07D417/14
CPC classification number: A61K31/496 , A61K31/405 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D498/04
Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
-
-
-
-
-
-
-
-
-
Search Results
312
records
(took 0.047 seconds)
